Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer

Journal of Surgical Oncology

Volumn 105, Issue 7, 2012, Pages 724-730

  Wu, Ying ^a,b   Yamada, Sohsuke ^a   Izumi, Hiroto ^a   Li, Zhi ^a,b   Shimajiri, Shohei ^a   Wang, Ke Yong ^a   Liu, Yun Peng ^b   Kohno, Kimitoshi ^a   Sasaguri, Yasuyuki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

disease free survival; gastric cancer; liver metastasis; prognosis; YB 1

Indexed keywords

UVOMORULIN; VIMENTIN; Y BOX BINDING PROTEIN 1;

ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GASTRECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER METASTASIS; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ADULT; AGED; CADHERINS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; VIMENTIN; Y-BOX-BINDING PROTEIN 1;

EID: 84859896506     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23030     Document Type: Article

References (40)

1. Fernandez-Fernandez FJ, Sesma P,: Gastric cancer. Lancet 2009; 374: 1594; author reply 1594-1595.
2. Shah MA, Kelsen DP,: Gastric cancer: A primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Cancer Netw 2010; 8: 437-447.
3. Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112.
4. Semba S, Kodama Y, Ohnuma K, et al.: Direct cancer-stromal interaction increases fibroblast proliferation and enhances invasive properties of scirrhous-type gastric carcinoma cells. Br J Cancer 2009; 101: 1365-1373.
5. Duarte I, Llanos O,: Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol 1981; 12: 237-242. (Pubitemid 11155994)
6. Kohno K, Izumi H, Uchiumi T, et al.: The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 2003; 25: 691-698. (Pubitemid 36850797)
7. Basaki Y, Hosoi F, Oda Y, et al.: Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007; 26: 2736-2746. (Pubitemid 46663838)
8. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, et al.: YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004; 59: 337-349. (Pubitemid 38509767)
9. Janz M, Harbeck N, Dettmar P, et al.: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002; 97: 278-282. (Pubitemid 34049016)
10. Evdokimova V, Tognon C, Ng T, et al.: Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15: 402-415.
11. Meng X, Ezzati P, Wilkins JA,: Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS ONE 2011; 6: e18715.
12. Shirabe K, Wakiyama S, Gion T, et al.: Hepatic resection for the treatment of liver metastases in gastric carcinoma: Review of the literature. HPB (Oxford) 2006; 8: 89-92.
13. Ohga T, Koike K, Ono M, et al.: Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56: 4224-4228. (Pubitemid 26305020)
14. Shino Y, Watanabe A, Yamada Y, et al.: Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995; 76: 2193-2201.
15. Domagala W, Lasota J, Dukowicz A, et al.: Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol 1990; 137: 1299-1304.
16. Nguyen DX, Bos PD, Massague J,: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
17. Chiang AC, Massague J,: Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
18. Amemiya H, Kono K, Itakura J, et al.: c-Met expression in gastric cancer with liver metastasis. Oncology 2002; 63: 286-296. (Pubitemid 36151324)
19. Finkbeiner MR, Astanehe A, To K, et al.: Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009; 28: 1421-1431.
20. Iwasa S, Yanagawa T, Fan J, et al.: Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res 2009; 29: 4751-4758.
21. Oda Y, Ohishi Y, Basaki Y, et al.: Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci 2007; 98: 1020-1026. (Pubitemid 46865386)
22. Teshima S, Kakizaki K, Saito T, et al.: Clinicopathological study for gastric cancer with liver metastasis. Ups J Med Sci 2002; 107: 61-70.
23. Dooley S, Said HM, Gressner AM, et al.: Y-box protein-1 is the crucial mediator of antifibrotic interferon-gamma effects. J Biol Chem 2006; 281: 1784-1795.
24. Yasen M, Kajino K, Kano S, et al.: The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res 2005; 11: 7354-7361. (Pubitemid 41507694)
25. Kamura T, Yahata H, Amada S, et al.: Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999; 85: 2450-2454. (Pubitemid 29244855)
26. Gluz O, Mengele K, Schmitt M, et al.: Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 2009; 27: 6144-6151.
27. Allan AL, Vantyghem SA, Tuck AB, et al.: Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006; 26: 87-98. (Pubitemid 46655481)
28. Fotovati A, Abu-Ali S, Wang PS, et al.: YB-1 bridges neural stem cells and brain-tumor initiating cells via its roles in differentiation and cell growth. Cancer Res 2011. 71: 5569-5578.
29. To K, Fotovati A, Reipas KM, et al.: Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010; 70: 2840-2851.
30. Ferrari D, Codeca C, Fiore J, et al.: Biomolecular markers in cancer of the tongue. J Oncol 2009; 2009: 412908.
31. Goetz MP, Rae JM, Suman VJ, et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
32. Townsend PA, Dublin E, Hart IR, et al.: BAG-i expression in human breast cancer: Interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data. J Pathol 2002; 197: 51-59. (Pubitemid 34450164)
33. Evdokimova V, Tognon C, Ng T, et al.: Reduced proliferation and enhanced migration: Two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009; 8: 2901-2906.
34. Basaki Y, Taguchi K, Izumi H, et al.: Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. Eur J Cancer 2010; 46: 954-965.
35. Jurchott K, Bergmann S, Stein U, et al.: YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003; 278: 27988-27996. (Pubitemid 36899994)
36. Bargou RC, Jurchott K, Wagener C, et al.: Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 447-450. (Pubitemid 27145688)
37. Tay WL, Yip GW, Tan PH, et al.: Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol 2009; 22: 282-290.
38. Woolley AG, Algie M, Samuel W, et al.: Prognostic association of YB-1 expression in breast cancers: A matter of antibody. PLoS ONE 2011; 6: e20603.
39. Ito Y, Yoshida H, Shibahara K, et al.: Y-box binding protein expression in thyroid neoplasms: Its linkage with anaplastic transformation. Pathol Int 2003; 53: 429-433. (Pubitemid 37000043)
40. Weichselbaum RR, Hellman S,: Oligometastases revisited. Nat Rev Clin Oncol 2011; 8: 378-382.